NMD Pharma will also present an update on the ongoing SYNAPSE-MG Phase 2b clinical trial of ignaseclant in generalized myasthenia gravisAarhus, ...
Interim observations from the Phase 2 TRAILHEAD study show continued improvement in handgrip strength, overall stability of elbow and shoulder ...
Researchers have identified a protein that’s critical to the development of skeletal muscle mass and strength and the tissue’s ability to metabolize glucose. They say their findings may lead to ...
Muscle loss (atrophy) due to inactivity is common after illness, injury, hospitalization or falls, and becomes increasingly ...
Researchers identified a molecular pathway that can limit muscle repair, a finding that may guide future muscular dystrophy treatments.
"Fast Track designation is an important regulatory milestone for PBGENE-DMD and reflects the significant unmet need in DMD," said Michael Amoroso, Chief Executive Officer of Precision BioSciences. "We ...
The Company’s lead candidate, EDG-5506, an investigational orally administered small molecule designed to protect injury-susceptible fast skeletal muscle fibers in dystrophinopathies, is advancing in ...
A study by Indiana University School of Medicine researchers sheds new light on the development and treatment of a rare form of muscular dystrophy. The study's findings were recently published in ...
Scientists have developed a specially formulated bioink, which contains microparticles engineered for sustained delivery of insulin-like growth factor-1 (IGF-1). This delivery enhances the formation ...
Skeletal muscle loss is a risk factor for developing dementia, according to a study being presented today at the annual meeting of the Radiological Society of North America (RSNA). Skeletal muscles ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results